{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:36:40Z","timestamp":1776422200851,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.ackd.2011.04.001","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T08:39:55Z","timestamp":1311583195000},"page":"290-299","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway"],"prefix":"10.1053","volume":"18","author":[{"given":"Hiddo J.","family":"Lambers Heerspink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2011.04.001_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2011.04.001_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/bmj.300.6729.904","article-title":"Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy","volume":"300","author":"Bjorck","year":"1990","journal-title":"BMJ"},{"key":"10.1053\/j.ackd.2011.04.001_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2011.04.001_bib7","first-page":"S174","article-title":"Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease","volume":"45","author":"Apperloo","year":"1994","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ackd.2011.04.001_bib8","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2011.04.001_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2011.04.001_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2011.04.001_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"key":"10.1053\/j.ackd.2011.04.001_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib16","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2011.04.001_bib17","first-page":"13","article-title":"How to improve renal outcome in diabetes and hypertension - the importance of early screening for and treatment of microalbuminuria","volume":"3","author":"de Zeeuw","year":"2009","journal-title":"Eur Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrneph.2009.111","article-title":"Pharmacology: defining the optimal dose of a new drug: a crucial decision","volume":"5","author":"Heerspink","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib19","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2011.04.001_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","article-title":"Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria","volume":"28","author":"Weir","year":"2010","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2011.04.001_bib22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib23","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1046\/j.1523-1755.2000.07506.x","article-title":"Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy","volume":"75","author":"Bos","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ackd.2011.04.001_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","article-title":"Dual renin-angiotensin system blockade at optimal doses for proteinuria","volume":"62","author":"Laverman","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3317\/jraas.2002.042","article-title":"Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?","volume":"3","author":"Laverman","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ackd.2011.04.001_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2011.04.001_bib28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","article-title":"Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease","volume":"60","author":"Jafar","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib29","doi-asserted-by":"crossref","first-page":"c137","DOI":"10.1159\/000315882","article-title":"Dual RAS therapy not on target, but fully alive","volume":"116","author":"Lambers Heerspink","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.ackd.2011.04.001_bib30","first-page":"646","article-title":"Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial","volume":"20","author":"Maione","year":"2007","journal-title":"J Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib32","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1097\/01.hjh.0000384007.86281.82","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease","volume":"28","author":"Schmieder","year":"2010","journal-title":"Journal of Hypertension"},{"key":"10.1053\/j.ackd.2011.04.001_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J Exp Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib34","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/HJH.0b013e3283310f92","article-title":"Renal and cardio-protective effects of direct renin inhibition: a systematic literature review","volume":"27","author":"Lambers Heerspink","year":"2009","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2011.04.001_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","article-title":"Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes","volume":"73","author":"Persson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib36","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2011.04.001_bib37","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ackd.2011.04.001_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1470320309342407","article-title":"Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension","volume":"10","author":"Andersen","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ackd.2011.04.001_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2011.04.001_bib40","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2011.04.001_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib42","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib43","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2011.04.001_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J Steroid Biochem"},{"key":"10.1053\/j.ackd.2011.04.001_bib46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrd1039","article-title":"Eplerenone","volume":"2","author":"Brown","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.ackd.2011.04.001_bib47","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2011.04.001_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2011.04.001_bib49","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/diacare.25.4.663","article-title":"A low-sodium diet potentiates the effects of losartan in type 2 diabetes","volume":"25","author":"Houlihan","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2011.04.001_bib50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00125-003-1303-5","article-title":"Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance","volume":"47","author":"Vedovato","year":"2004","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2011.04.001_bib51","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/dc08-2297","article-title":"Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake","volume":"32","author":"Ekinci","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2011.04.001_bib52","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2011.04.001_bib53","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2011.04.001_bib54","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2011.04.001_bib55","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1097\/HJH.0b013e32833eaf34","article-title":"Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers","volume":"28","author":"Lely","year":"2010","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2011.04.001_bib56","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/ndt\/gfp776","article-title":"Diuretic uptitration with half dose combined ACEI + ARB better decrease proteinuria than combined ACEI + ARB uptitration","volume":"25","author":"Esnault","year":"2010","journal-title":"Nephrol Dial Transplant"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559511000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559511000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T17:43:33Z","timestamp":1638121413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559511000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1548559511000577"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2011.04.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}